Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven A Feldman

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2014
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with responsePaul F Robbins, Sadik H Kassim, Thai L N Tran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 LevelsJames N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.
Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 16, 2010
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitisMaria R Parkhurst, James C Yang, Russell C Langan, et al.
Cell Reports. Medicine|January 21, 2026
c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumorsHyatt Balke-Want, Vimal Keerthi, Maria Del Carmen Arenas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1Paul F Robbins, Richard A Morgan, Steven A Feldman, et al.
Cancer Cell|January 26, 2024
Inosine induces stemness features in CAR-T cells and enhances potencyDorota D Klysz, Carley Fowler, Meena Malipatlolla, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Inosine Induces Stemness Features in CAR T cells and Enhances PotencyDorota D Klysz, Carley Fowler, Meena Malipatlolla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host DiseaseJennifer N Brudno, Robert P T Somerville, Victoria Shi, et al.
Cancer Discovery|January 8, 2025
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCLYi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2014
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with responsePaul F Robbins, Sadik H Kassim, Thai L N Tran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 LevelsJames N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.
Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 16, 2010
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitisMaria R Parkhurst, James C Yang, Russell C Langan, et al.
Cell Reports. Medicine|January 21, 2026
c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumorsHyatt Balke-Want, Vimal Keerthi, Maria Del Carmen Arenas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1Paul F Robbins, Richard A Morgan, Steven A Feldman, et al.
Cancer Cell|January 26, 2024
Inosine induces stemness features in CAR-T cells and enhances potencyDorota D Klysz, Carley Fowler, Meena Malipatlolla, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Inosine Induces Stemness Features in CAR T cells and Enhances PotencyDorota D Klysz, Carley Fowler, Meena Malipatlolla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host DiseaseJennifer N Brudno, Robert P T Somerville, Victoria Shi, et al.
Cancer Discovery|January 8, 2025
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCLYi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, et al.
Pageof 7